Clinical trials: Prostate
Prostate Cancer Metastatic
Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Primary Objective: To compare the radiographic progression-free survival (rPFS) (using Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 for tumor lesions and Prostate Cancer Working Group 2 (PCWG2) criteria for bone scan…
- Trial name
- CARD (NCT02485691)
- Testing
- cabazitaxel XRP6258, enzalutamide, abiraterone acetate
- Where
- 65 sites in Austria, Belgium and 11 more
- Volunteers
- 255 people
- Sponsor
- Sanofi
Prostatic Hyperplasia
A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.
Dutasteride and tamsulosin are to treat benign prostatic hyperplasia. Studies show that when given together, there is more improvement in symptoms than either drug alone.
- Trial name
- NCT00609596
- Testing
- GI198745
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Non-small Cell Lung Cancer, Breast Cancer
Safety Study of Imexon Plus Docetaxel in Lung, Breast or Prostate Cancer Patients
Protocol AMP-010 is a Phase 1b study of imexon plus docetaxel for patients with previously treated breast cancer, previously treated lung cancer or hormone refractory prostate cancer.
- Conditions
- Non-small Cell Lung Cancer, Breast Cancer, Prostate Cancer
- Trial name
- NCT00327288
- Testing
- imexon, docetaxel
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- AmpliMed Corporation
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer
Study to Evaluate CCS1477 in Advanced Tumours
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid…
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
- Trial name
- NCT03568656
- Testing
- CCS1477, Abiraterone acetate, Enzalutamide
- Where
- 19 sites in United States, France and 4 more
- Volunteers
- 219 people
- Sponsor
- CellCentric Ltd.
Metastatic Castration Resistant Prostate Cancer
A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.
This is a phase I study evaluating tolerability, pharmacokinetics, and preliminary efficacy of HC-1119 in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT03774056
- Testing
- HC-1119
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Hinova Pharmaceuticals Inc.
Biochemical Recurrence of Malignant Neoplasm of Prostate
64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)
The aim of this study is to determine the safety and efficacy of 64Cu-SAR-bisPSMA and determine the ability of 64Cu-SAR-bisPSMA Positron emission tomography (PET)/computed tomography (CT) to correctly detect the recurrence of…
- Trial name
- COBRA (NCT05249127)
- Testing
- 64Cu-SAR-bisPSMA
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Clarity Pharmaceuticals Ltd
Prostate Cancer
Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.
The purpose of the protocol, is to assess the feasibility of conducting a larger trial to evaluate the effect of a psychological intervention on the well-being of patients on luteinizing hormone-releasing hormone (LHRH) analogs…
- Trial name
- EXPEDIENT (NCT01562522)
- Testing
- Psychological counseling
- Where
- 3 sites in Netherlands
- Volunteers
- 6 people
- Sponsor
- Ipsen
Advanced Solid Tumors, Breast Cancer
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with…
- Conditions
- Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
- Trial name
- NCT07038369
- Testing
- ATV-1601, ATV-1601 + Fulvestrant
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 134 people
- Sponsor
- Atavistik Bio, Inc
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Omega Study: Evaluation of the Safety and Efficacy of the Omega System for the Treatment of BPH
The ProArc Medical Omega system is a prostatic reshaping device that is designed to treat Lower Urinary Tract Symptoms (LUTS) due to BPH.
- Trial name
- NCT04627701
- Testing
- Omega
- Where
- 4 sites in Israel, New Zealand
- Volunteers
- 26 people
- Sponsor
- ProArc Medical
Prostate Cancer
CART-PSMA Cells for Advanced Prostate Cancer
This is a single center, open-label phase 1 study to assess the safety and feasibility of PSMA-specific CAR modified autologous T cells (CART-PSMA cells) in patients with advanced prostate cancer.
- Trial name
- NCT05656573
- Testing
- CART-PSMA cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nova Therapeutics LLC
Prostate Cancer, Neoplasm Metastasis
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00459654
- Testing
- Radium-223 dichloride (BAY88-8223), Saline
- Where
- 3 sites in Sweden, United Kingdom
- Volunteers
- 64 people
- Sponsor
- Bayer
Breast Cancer, Lung Cancer
Sample Collection for Ongoing Research and Product Evaluation Study
The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors.
- Conditions
- Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer
- Trial name
- SCORE (NCT07318051)
- Where
- United States
- Volunteers
- 9,600 people
- Sponsor
- Natera, Inc.
Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
A Randomized Triple-Blind Placebo-Controlled Study to Evaluate the Effects of a Supplement on Lower Urinary Tract Symptoms in Men.
This study aims to evaluate the effects of the ProstaThrive™ supplement on lower urinary tract symptoms (LUTS) in men. It is a 90-day virtual, randomized, placebo-controlled trial with 80 male participants aged 40 and above.
- Conditions
- Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, Erectile Dysfunction
- Trial name
- NCT06504472
- Testing
- ProstaThrive™ Supplement
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Optimale
Prostate Cancer
Vaccine Treatment for Hormone Refractory Prostate Cancer
This 2-phase study will determine the safety of treating patients with prostate cancer with the genetically engineered HyperAcute-Prostate cancer vaccine.
- Trial name
- NCT00105053
- Testing
- HyperAcute-Prostate Cancer Vaccine
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NewLink Genetics Corporation
Prostatic Hyperplasia, Acute Urinary Retention
ALFAURUS : A DB Randomized Parallel Group Study of Alfuzosin 10mg OD vs Placebo in the Management of AUR in Patients With a 1st Episode Due to BPH
To assess the efficacy of alfuzosin 10mg OD in the management of acute urinary retention associated with BPH. To assess the safety of alfuzosin in this population and health care consumption.
- Trial name
- NCT00290030
- Testing
- Alfuzosin
- Volunteers
- 800 people
- Sponsor
- Sanofi
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive bladder (OAB) symptoms in men who have been treated for benign prostatic hyperplasia (BPH) with tamsulosin hydrochloride for at least 6…
- Conditions
- Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Overactive Bladder
- Trial name
- NCT00771394
- Testing
- Tamsulosin hydrochloride, Solifenacin succinate
- Where
- 8 sites in Japan
- Volunteers
- 638 people
- Sponsor
- Astellas Pharma Inc
Prostate Cancer
A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
The primary purpose of this study was to compare the time to prostate cancer progression (pathological or therapeutic progression) between patients treated with enzalutamide versus patients undergoing active surveillance.
- Trial name
- ENACT (NCT02799745)
- Testing
- Enzalutamide, Active Surveillance
- Where
- 54 sites in United States, Canada
- Volunteers
- 227 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Castration-resistant Prostate Cancer
A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer
This clinical trial is to evaluate the safety of the combination of DCVAC/PCa with ONCOS-102 in men with castration-resistant advanced metastatic prostate cancer, who have progressed following initial therapy with either hormones…
- Trial name
- NCT03514836
- Testing
- DCVac/PCa, Cyclophosphamide
- Where
- Czechia
- Volunteers
- 5 people
- Sponsor
- SOTIO a.s.